Ziel Biopharma Ltd.

Castletroy, Ireland

Ziel Biopharma Ltd.

Castletroy, Ireland

Time filter

Source Type

Sanz-Nogues C.,National University of Ireland | Horan J.,Ziel Biopharma Ltd. | Thompson K.,Center for Microscopy and Imaging AnatomyNational University of Ireland GalwayNewcastle RoadGalway Ireland | Howard L.,National University of Ireland | And 3 more authors.
Journal of Biomedical Materials Research - Part A | Year: 2015

Microcapsules made of sodium cellulose sulphate (SCS) and poly-diallyl-dimethyl-ammonium chloride (pDADMAC) have been employed to encapsulate a wide range of established cell lines for several applications. However, little is known about the encapsulation of primary cells including human mesenchymal stem cells (hMSCs). Human MSCs are of interest in regenerative medicine applications due to pro-angiogenic, anti-inflammatory and immunomodulatory properties, which result from paracrine effects of this cell type. In the present work we have encapsulated primary hMSCs and hMSC-TERT immortalized cells and compared their behavior and in vitro angiogenic potential. We found that, although both cell types were able to secret angiogenic factors such as VEGF, there was a marked reduction of primary hMSC viability compared to hMSC-TERT cells when cultured in these microcapsules. Moreover, this applied to other primary cell cultures such as primary human fibroblasts but not to other cell lines such as human embryonic kidney 293 (HEK293) cells. We found that the microcapsule membrane had a molecular weight cut-off below a critical size, which caused impairment in the diffusion of essential nutrients and had a more detrimental effect on the viability of primary cell cultures compared to cell lines and immortalized cells. © 2015 Wiley Periodicals, Inc.


Stiegler P.,Medical University of Graz | Matzi V.,Medical University of Graz | Pierer E.,Medical University of Graz | Hauser O.,Ziel Biopharma Ltd | And 10 more authors.
Xenotransplantation | Year: 2010

Introduction: Transplanted cells, especially islet cells, are likely to become apoptotic due to local hypoxia leading to graft dysfunction. Isolated pancreatic islet cells depend on the diffusion of oxygen from the surrounding tissue; therefore, access to sufficient oxygen supply is beneficial, particularly when microcapsules are used for immunoisolation in xenotransplantation. The aim of this study was to create a prevascularized site for cell transplantation in rats and test its effectiveness with microencapsulated HEK293 cells. Methods: The combination of implantation of a foam dressing, vacuum-assisted wound closure (foam+VAC) and hyperbaric oxygenation (HBO) was used in 40 Sprague-Dawley rats. Blood flow and vascular endothelial growth factor (VEGF) levels were determined. Sodium cellulose sulphate (SCS)-microencapsulated HEK293 cells were xenotransplanted into the foam dressing in rats pre-treated with HBO, and angiogenesis and apoptosis were assessed. Results: Vessel ingrowth and VEGF levels increased depending on the duration of HBO treatment. The area containing the foam was perfused significantly better in the experimental groups when compared to controls. Only a small amount of apoptosis occurs in SCS-microencapsulated HEK293 cells after xenotransplantation. Conclusion: As ischemia-damaged cells are likely to undergo cell death or loose functionality due to hypoxia, therefore leading to graft dysfunction, the combination foam+VAC and HBO might be a promising method to create a prevascularized site to achieve better results in xenogeneic cell transplantation. © 2010 John Wiley & Sons A/S.


Sanz-Nogues C.,National University of Ireland | Horan J.,Ziel Biopharma Ltd. | Thompson K.,National University of Ireland | Howard L.,National University of Ireland | And 4 more authors.
Journal of Biomedical Materials Research - Part A | Year: 2015

Microcapsules made of sodium cellulose sulphate (SCS) and poly-diallyl-dimethyl-ammonium chloride (pDADMAC) have been employed to encapsulate a wide range of established cell lines for several applications. However, little is known about the encapsulation of primary cells including human mesenchymal stem cells (hMSCs). Human MSCs are of interest in regenerative medicine applications due to pro-angiogenic, anti-inflammatory and immunomodulatory properties, which result from paracrine effects of this cell type. In the present work we have encapsulated primary hMSCs and hMSC-TERT immortalized cells and compared their behavior and in vitro angiogenic potential. We found that, although both cell types were able to secret angiogenic factors such as VEGF, there was a marked reduction of primary hMSC viability compared to hMSC-TERT cells when cultured in these microcapsules. Moreover, this applied to other primary cell cultures such as primary human fibroblasts but not to other cell lines such as human embryonic kidney 293 (HEK293) cells. We found that the microcapsule membrane had a molecular weight cut-off below a critical size, which caused impairment in the diffusion of essential nutrients and had a more detrimental effect on the viability of primary cell cultures compared to cell lines and immortalized cells. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 103A: 3676-3688, 2015. © 2015 Wiley Periodicals, Inc.


Patent
Ziel Biopharma Ltd | Date: 2010-04-07

The present invention relates to an apparatus and a method for producing microcapsules. The apparatus according to the invention comprises at least one bead generator, having at least one nozzle passed by a liquid during operation, with a liquid reservoir arranged before the nozzle. The liquid reservoir comprises a membrane in the region of at least one boundary wall for generating a mechanical oscillation in the liquid. The apparatus comprises at least one reaction and transport device passed by a reaction medium, in which the beads generated in the bead generator are received. Microcapsules are formed during a predetermined reaction time period between at least one first polymeric component of the beads and at least one second polymeric component in the reaction medium and are transported along a reaction path. The apparatus is characterized in that at least one electrode, movable substantially parallel to the nozzle axis by a drive, is arranged between the bead generator and the reaction and transport device, which generates an electric field between an outlet region of the nozzle and the electrode for influencing the bead properties. The invention further includes a use of the apparatus for producing microcapsules and a method for controlling the apparatus.

Loading Ziel Biopharma Ltd. collaborators
Loading Ziel Biopharma Ltd. collaborators